Contact this trialFirst, we need to learn more about you.
MDM2 Inhibitor
KRT-232 + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Seattle, Washington
This trial is testing a new drug combination for myelofibrosis, a rare blood cancer. The goal is to find the best dose of the new drug to give with another drug that is already used for this disease.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.